CI622D デキサメタゾン溶出人工内耳を移植された成人におけるパフォーマンスおよび聴覚関連の転帰を、標準人工内耳 (CI622) を移植された成人と比較した (DETECT)
新たに移植された成人集団における標準スリムストレート電極 (CI622) と比較して、インピーダンスの低減におけるデキサメタゾン溶出スリムストレート電極 (CI622D) の有効性を評価する、極めて重要な前向き多施設ランダム化対照盲検調査言語後、両側性、中等度から重度の感音性難聴。
This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Manchester、イギリス
- Manchester Royal Infirmary
-
-
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア
- Westmead Private Hospital
-
Sydney、New South Wales、オーストラリア
- Royal Prince Alfred Hospital
-
Sydney、New South Wales、オーストラリア
- Macquarie University
-
-
Victoria
-
Melbourne、Victoria、オーストラリア
- St Vincent Private Hospital
-
Melbourne E.、Victoria、オーストラリア
- Royal Victorian Eye and Ear Hospital
-
-
-
-
Freiburg Im Breisgau
-
Freiburg im Breisgau、Freiburg Im Breisgau、ドイツ
- Universitätsklinikum Freiburg
-
-
Lower Saxony
-
Hanover、Lower Saxony、ドイツ
- Medizinische Hochschule Hannover
-
-
-
-
-
Lille、フランス
- Centre Hospitalier Universitaire de Lille
-
Paris、フランス
- Hôpital Universitaire Pitié-Salpêtrière
-
Toulouse、フランス
- Centre Hospitalier Universitaire Toulouse
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 18 years or older (at time of consent)
- Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
- Meets local candidacy criteria for cochlear implantation
- Compromised functional hearing with a hearing aid in the ear to be implanted
- Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
- Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
- Candidate is proficient in the language used to assess speech perception performance
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Planned for a partial insertion of the electrode array
- Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
- Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
- Active autoimmune disease or active immunosuppressive therapy
- Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
- Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
- Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
- Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
- Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
- History of bacterial meningitis
- Known allergic reaction or contraindication to dexamethasone or corticosteroids
- Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
- Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
- Prior cochlear implantation, in either ear
- Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
- Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
- Women who are pregnant
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
- Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
- Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
- Subjects recruited at a French site who are not affiliated with social security
- Subjects recruited at a French site who are under legal protection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:CI622D
Investigational Medical Device (IMD) |
A dexamethasone-eluting Slim Straight electrode |
|
アクティブコンパレータ:CI622
An approved medical device |
A standard Slim Straight electrode |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Difference in the mean impedance between CI622D and CI622
時間枠:6 months post-activation
|
Mean monopolar impedance measured across the active electrodes of the implant for each participant. |
6 months post-activation
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
時間枠:Throughout study (12 months)
|
Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group |
Throughout study (12 months)
|
|
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
時間枠:Pre-implantation to 6 months post activation
|
The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline. |
Pre-implantation to 6 months post activation
|
|
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
時間枠:Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
時間枠:Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
時間枠:Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
時間枠:Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
時間枠:Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
時間枠:Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
時間枠:Activation, 12 months post-activation
|
Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622 |
Activation, 12 months post-activation
|
|
Characterization of mean estimated sound processor battery life for CI622D and CI622
時間枠:12 months post-activation
|
The estimated sound processor battery life (hours per day) as calculated by the programming software |
12 months post-activation
|
|
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
時間枠:Pre-implantation to 12 months post-activation
|
Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability). |
Pre-implantation to 12 months post-activation
|
|
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
時間枠:Pre-implantation to 12 months post-activation
|
Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health". |
Pre-implantation to 12 months post-activation
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Antje Aschendorff、University Hospital Freiburg
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CLTD5815
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。